2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequency
2014
Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers
Adeniran AJ, Hui P. Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. Expert Review Of Endocrinology & Metabolism 2014, 9: 571-577. PMID: 30736195, DOI: 10.1586/17446651.2014.951635.Peer-Reviewed Original ResearchBRAF V600E mutationPapillary thyroid carcinomaThyroid carcinomaV600E mutationPAX8/PPARγ rearrangementsSubsequent core needle biopsyUndetermined significance/atypiaFine needle aspiration cytologyBRAF V600E mutation testingLow-stage diseaseCore needle biopsyRoutine clinical practiceAggressive tumor behaviorNeedle aspiration cytologyBRAF mutation testingFine-needle aspiration specimensUndetermined significance categoryIndeterminate fine-needle aspiration cytologyNeedle aspiration specimensPredictability of malignancyCommon genetic alterationsMutation testingRET/papillary thyroid carcinomaThyroid fine-needle aspiration specimensIndependent predictors
2012
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct
Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012, 60: 1052-1059. PMID: 22335197, DOI: 10.1111/j.1365-2559.2011.04149.x.Peer-Reviewed Original Research
2011
Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study
Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC. Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. Thyroid 2011, 21: 717-723. PMID: 21568726, DOI: 10.1089/thy.2011.0021.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryChildDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPoint MutationPolymorphism, Single-Stranded ConformationalProspective StudiesProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid GlandThyroid Neoplasms